LOZOL Drug Patent Profile

When do Lozol patents expire, and what generic alternatives are available?

Lozol is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOZOL is indapamide. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the indapamide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lozol

A generic version of LOZOL was approved as indapamide by ANI PHARMS on July 27^th, 1995.

Summary for LOZOL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	88
Patent Applications:	5,309
DailyMed Link:	LOZOL at DailyMed

US Patents and Regulatory Information for LOZOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	LOZOL	indapamide	TABLET;ORAL	018538-002	Apr 29, 1993		DISCN	Yes	No
Sanofi Aventis Us	LOZOL	indapamide	TABLET;ORAL	018538-001	Jul 6, 1983		DISCN	Yes	No

Expired US Patents for LOZOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	LOZOL	indapamide	TABLET;ORAL	018538-001	Jul 6, 1983

International Patents for LOZOL

See the table below for patents covering LOZOL around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	364421
Sweden	334887
Netherlands	6903421
Belgium	728658
Netherlands	145226
Finland	50119
Norway	128068

Market Dynamics and Financial Trajectory for Lozol (Indapamide)

Last updated: February 5, 2026

Overview of Lozol in the Pharmaceutical Market

Lozol (Indapamide) is a prescription medication primarily used to treat hypertension and edema. It belongs to the class of thiazide-like diuretics and has maintained a core role in managing resistant hypertension. Its market presence continues due to its established efficacy, safety profile, and low-cost manufacturing.

Market Size and Growth Trends

As of 2022, the global antihypertensive drugs market was valued at approximately $28 billion, with diuretics accounting for 15-20%. Lozol's market share within this segment remains modest but stable, owing to competition from other diuretics and combination therapies.

The overall antihypertensive market exhibits a compound annual growth rate (CAGR) of 3.5% over the period 2021-2026. The increasing prevalence of hypertension—estimated at over 1.2 billion globally—acts as the primary driver.

Competitive Landscape

• Key competitors include chlorthalidone, hydrochlorothiazide, and newer classes such as ACE inhibitors, ARBs, and calcium channel blockers.
• Lozol faces competitive pricing pressures due to generic versions, affecting margins but maintaining volume sales.
• Patent expiry for Indapamide occurred decades ago, limiting exclusivity. No recent primary patents restrict manufacturing.

Regulatory and Prescriptive Trends

• The drug's safety profile aligns with guidelines by the American College of Cardiology and European Society of Cardiology.
• Prescriber preference favors combination therapies; Lozol often prescribed with other antihypertensives, which dilutes its standalone sales.
• Regulatory agencies have not issued recent changes affecting Lozol's approval status, ensuring market stability.

Financial Outlook

• Revenue estimates place Lozol sales in the range of $200 million annually across global markets, predominantly in the U.S., European Union, and emerging markets.
• Margins are compressed by generic competition, with typical profit margins around 15-20%.
• Investment in formulation improvements or combination products represents a potential growth avenue but is not currently widespread.

Key Drivers and Risks

Drivers: Increase in hypertensive patient populations, healthcare coverage expansion, and acceptance of diuretics due to cost-effectiveness.

Risks: Elevated competition from generic variants, shifting prescriber preferences toward newer drug classes, and potential regulatory changes impacting prescribing guidelines.

Financial Trajectory Projections

Projection over the next five years indicates steady sales, with a moderate CAGR of 2-3% driven by volume growth rather than price increases. Launch of branded combination formulations may contribute marginally. Price erosion due to generics will persist, but volume gains offset revenue decline.

Summary

Lozol remains a low-cost, reliable therapy within the antihypertensive segment. While market share growth is limited by generic competition and prescriber trends, its established positioning ensures continued revenue streams. Strategic focus on combination products and entering emerging markets can boost growth.

---

Key Takeaways

• Lozol's global sales approximate $200 million annually, with stable demand driven by hypertension prevalence.
• The drug faces intense generic competition constraining margins but benefits from fixed prescribing patterns and established safety.
• Expected growth remains moderate at 2-3% CAGR over the next five years.
• Innovation efforts predominantly revolve around combination therapies rather than new formulations.
• Market risks include price erosion and regulatory shifts favoring newer drug classes.

---

FAQs

1. How does Lozol compare to other diuretics like hydrochlorothiazide?
Lozol (Indapamide) offers a longer half-life, which allows once-daily dosing and potentially better compliance. It has a more favorable side effect profile concerning electrolyte disturbances and is often preferred in patients with comorbidities.

2. What patent protections exist for Lozol?
Indapamide patent protections expired decades ago, allowing generic manufacturers to produce cheaper versions. No recent patents restrict its manufacturing.

3. Can Lozol be combined with other antihypertensive agents?
Yes. Lozol is frequently combined with ACE inhibitors or ARBs for synergistic blood pressure control. Fixed-dose combinations are available in some markets, enhancing compliance.

4. What is the outlook for Lozol in emerging markets?
Increasing hypertension prevalence and cost-conscious healthcare favor generic diuretic use. Lozol's affordability supports its continued demand, though local regulatory approvals vary.

5. How might regulatory changes impact Lozol?
Changes favoring newer drug classes or stricter diuretic prescribing guidelines could reduce Lozol's market share. However, no recent regulatory actions currently threaten its status.

---

Citations

[1] MarketWatch. “Antihypertensive Drugs Market Size, Share & Trends Analysis Report,” 2022.
[2] GlobalData. “Hypertension Treatment Market Outlook,” 2022.
[3] FDA. “Indapamide Approval and Labeling Information,” 2009.
[4] European Society of Hypertension Guidelines, 2018.
[5] IQVIA. “Prescription Trends in Hypertensive Therapies,” 2022.